載入...
Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation
Giant cell tumor of bone (GCTB) is a locally aggressive lesion of intermediate malignancy. Malignant transformation of GCTB is a rare event. In 2013, the humanized monoclonal antibody against receptor activator of nuclear factor-κb-Ligand (RANKL) denosumab was approved for treatment of advanced GCTB...
Na minha lista:
| 發表在: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group UK
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7952552/ https://ncbi.nlm.nih.gov/pubmed/33707617 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85319-x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|